Project Name: Heart Failure In-reach Pharmacist St George’s University Hospitals

Organisation(s): 

Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London W12 7FQ, and,

St George’s University Hospitals NHS Foundation Trust

Project Summary: 

The main objective of the Collaborative Working Project is to improve the quality of care delivered to Heart Failure (HF) patients under the care of the St George’s University Hospitals NHS Foundation Trust (The” Trust”) in line with European Society of Cardiology ESC guidance1. This CWP will involve the improvement of the current hospital-based specialist HF service at the Trust through the deployment of an “in-reach” pharmacist HF specialist. Additionally, the CWP aims at establishing a case for future funding of the HF service by the Trust. The project will be looking to improve against the baseline % measures for The Trust – patients receiving/being prescribed (including all patients admitted with less than 24 hours admission):

  • input from specialist;
  • received discharge planning;
  • referral to HF specialist
  • Implementation of the local treatment protocol;
  • Patient education of Heart Failure with a personalised Care Plan

Planned Milestones:

MilestoneDescription
1Confirmation of the employment of pharmacist ; pharmacist on-boarding and familiarisation; 
complete collection of baseline aggregate comparator data for the project outcomes. 
Implement in-patient strategies/protocols and procedures governing the clinical operations of the HF Service. 
Begin clinical operations according to the developed protocols, monitor and collect data.
2Carry out 3 months of clinical operations according to the developed protocols, NHS Trust to monitor and collect data, provide anonymised report.
3

Carry out 3 months of clinical operations according to the developed protocols, NHS Trust to monitor and collect data, provide anonymised 

Submission of business case by SGUH HF team to relevant body within SGUH

4Carry out 3 months of clinical operations according to the developed protocols, NHS Trust to monitor and collect data, provide anonymised
5Carry out 3 months of clinical operations according to the developed protocols, monitor and collect data, provide anonymised report
6Carry out 3 months of clinical operations according to the developed protocols, monitor and collect data, provide anonymised report
7Carry out 3 months of clinical operations according to the developed protocols, monitor and collect data, provide anonymised report
8Submit final CWP report to Novartis within 6 months completion of the clinical work

 

Expected Benefits:

For the Patient:

  • Improved access to evidence based treatment;
  • more equitable and consistent care and access to care.
  • enhanced experience for patients and their carers who live with HF.
  • Increased access to Education on heart failure will enable patients to self manage their condition
  • A personalised heart Failure care plan will help the patient to self manage their condition

For the NHS:

  • Increase the overall quality of care and improve equity of access to specialist care for patients with HF;
  • Increase proportion of patients with HF being managed in accordance with the ESC 2021 chronic heart failure guidelines
  • Reduction in waiting list times

For Novartis:

  • Further opportunities for the appropriate use of cardiology licensed medicines in line with NICE guidelines, including Novartis’s medicine;
  • Improved reputation;
  • Improved professional and transparent relationship and trust between Novartis and the NHS

Start Date & Duration: September 2022 for 24 months

UK2308241147
02-Aug-2023